General
Preferred name
ROTIGAPTIDE
Synonyms
Rotigaptide TFA ()
ZP 123 ()
ZP123 ()
Gap (Wyeth) ()
ZP-123 (Zealand) ()
ZP-123 ()
P&D ID
PD049169
CAS
355151-12-1
Tags
available
drug candidate
Drug indication
Cardiac arrhythmias
Drug Status
investigational
Max Phase
Phase 2
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Rotigaptide is a hexapeptide developed originally by Wyeth, as an anti-arrhythmic agent. It promotes electrical coupling between ventricular myocytes by increasing gap junction conductance . A recent study showed reduction in myocardial infarction size in a porcine model and protection from IRI-related endothelial dysfunction in man. Rotigaptide may thus have therapeutic potential in the treatment of myocardial infarction . (GtoPdb)
Compound Sets
7
ChEMBL Drugs
CHEMBL450656
DrugBank
DB13067
DrugMAP
DMXB9RS
Guide to Pharmacology
9214
MedChem Express Bioactive Compound Library
HY-106225
ReFrame library
TargetMol Bioactive Compound Library
T16790L
External IDs
20
Properties
(calculated by RDKit )
Molecular Weight
617.28
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
7
Rotatable Bonds
12
Ring Count
3
Aromatic Ring Count
1
cLogP
-3.39
TPSA
240.57
Fraction CSP3
0.54
Chiral centers
5.0
Largest ring
6.0
QED
0.12
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Cytoskeletal Signaling
cytoskeleton
Target
Cx43
Gap Junction Protein
Source data